Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 26, 2022; 10(30): 11074-11081
Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.11074
Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.11074
Bone marrow metastatic neuroendocrine carcinoma with unknown primary site: A case report and review of the literature
Xue-Bing Shi, Wen-Xia Deng, Department of Medical Oncology, Tongling People’s Hospital, Tongling 244000, Anhui Province, China
Feng-Xiang Jin, Department of Hematology, Tongling People’s Hospital, Tongling 244000, Anhui Province, China
Author contributions: Shi XB participated in the treatment of the patient, collecting and analyzing the clinical data, and writing the manuscript; Deng WX contributed to the treatment of the patient, data analysis, and revision of the manuscript; Jin FX was involved in guiding the treatment of the patient and designing the research; all authors read and approved the final manuscript.
Informed consent statement: Written informed consent was obtained from the patient’s offspring for publication of this case report.
Conflict-of-interest statement: The authors declare that they have no conflicts of interests.
CARE Checklist (2016) statement: We have read the CARE Checklist (2016), and this manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xue-Bing Shi, MD, Attending Doctor, Department of Medical Oncology, Tongling People’s Hospital, No. 468 Bijiashan Road, Tongguan District, Tongling 244000, Anhui Province, China. sxbtlph@163.com
Received: June 10, 2022
Peer-review started: June 10, 2022
First decision: June 27, 2022
Revised: July 8, 2022
Accepted: August 23, 2022
Article in press: August 23, 2022
Published online: October 26, 2022
Peer-review started: June 10, 2022
First decision: June 27, 2022
Revised: July 8, 2022
Accepted: August 23, 2022
Article in press: August 23, 2022
Published online: October 26, 2022
Core Tip
Core Tip: Neuroendocrine carcinoma (NEC) rarely occurs in the bone marrow. We report a patient diagnosed with bone marrow metastatic NEC, bone marrow necrosis and secondary myelofibrosis. As extensive imaging examinations did not show the primary lesion, we speculated that the primary tumor might regress spontaneously or merely not be identified due to lack of positron emission tomography with gallium peptide. Because of the poor general physical condition with an Eastern Cooperative Oncology Group performance status of 3-4, chemotherapy was abandoned, and everolimus as well as the best supportive therapies were given. Unfortunately, the patient’s condition continued to deteriorate and finally passed away.